The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

Gynecologic Oncology

Volumn 110, Issue 3, 2008, Pages 383-389

  Johnson, Christine C ^a   Kessel, Bruce ^b,c   Riley, Thomas L ^d   Ragard, Lawrence R ^e   Williams, Craig R ^d   Xu, Jian Lun ^f   Buys, Saundra S ^g  

^a HENRY FORD HOSPITAL   (United States)

^b PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e WESTAT   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF UTAH   (United States)

Author keywords

CA 125; Epidemiology; Race ethnicity

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CIGARETTE SMOKING; ETHNIC DIFFERENCE; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LIFESTYLE; MAJOR CLINICAL STUDY; OBESITY; OVARY CANCER; PRIORITY JOURNAL; REGRESSION ANALYSIS;

AGE FACTORS; AGED; CA-125 ANTIGEN; ETHNIC GROUPS; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 50349100794     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.05.006     Document Type: Article

References (32)

1. Verheijen R.H., Mensdorff-Pouilly S., van Kamp G.J., and Kenemans P. CA 125: fundamental and clinical aspects. Semin Cancer Biol 9 (1999) 117-124
2. Duffy M.J., Bonfrer J.M., Kulpa J., Rustin G.J., Soletormos G., Torre G.C., et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15 (2005) 679-691
3. Bast R.C., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 (2005) 274-281
4. Karlan B.Y., and McIntosh M. The quest for ovarian cancer's holy grail: can CA-125 still be the chalice of early detection?. J Clin Oncol 25 (2007) 1303-1304
5. Baron A.T., Boardman C.H., Lafky J.M., Rademaker A., Liu D., Fishman D.A., et al. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 306-318
6. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99 (2005) 267-277
7. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23 (2005) 7919-7926
8. Prorok P.C., Andriole G.L., Bresalier R.S., Buys S.S., Chia D., Crawford E.D., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21 (2000) 273S-309S
9. Pauler D.K., Menon U., McIntosh M., Symecko H.L., Skates S.J., and Jacobs I.J. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10 (2001) 489-493
10. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., and York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 22 (2001) 348-366
11. Yin B.W., Dnistrian A., and Lloyd K.O. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98 (2002) 737-740
12. Whitehouse C., and Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 88 (2003) S152-S157
13. Koper N.P., Thomas C.M.G., Massuger L.F.A.G., van der Mooren M.J., Kiemeney L.A.L.M., and Verbeek A.L.M. Serum CA 125 concentrations in women of different ages, hormonal statuses, or clinical conditions. Int J Gynecol Cancer 7 (1997) 405-411
14. Hermsen B.B.J., von Mensdorff-Pouilly S., Berkhof J., van Diest P.J., Gille J.J.P., Menko F.H., et al. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 25 (2007) 1383-1389
15. In: Gohagan J.K., Levin D.L., Prorok P.C., and Sullivan D. (Eds). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 6S (2000) 249S-406S
16. Buys S.S., Partridge E., Greene M.H., Prorok P.C., Reding D., Riley T.L., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193 (2005) 1630-1639
17. Zeimet A.G., Muller-Holzner E., Marth C., Daxenbichler G., and Dapunt O. Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril 59 (1993) 1028-1035
18. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
19. Takami M., Sakamoto H., Ohtani K., Takami T., and Satoh K. An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery. Cancer Lett 121 (1997) 69-72
20. Bon G.G., Kenemans P., Verstraeten R., van Kamp G.J., and Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 174 (1996) 107-114
21. Crump C., McIntosh M.W., Urban N., Anderson G., and Karlan B.Y. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 9 (2000) 1107-1111
22. Grover S., Quinn M.A., Weideman P., and Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 79 (1992) 511-514
23. Grover S., Quinn M.A., Weideman P., and Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 79 (1992) 511-514
24. Kurihara T., Mizunuma H., Obara M., Andoh K., Ibuki Y., and Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 69 (1998) 192-196
25. Karabacak O., Ilgin N., Tiras B., Gursoy R., and Himmetoglu O. Influence of exogenous estrogen administration on serum CA-125 originating from the endometrium. Int J Gynaecol Obstet 76 (2002) 169-172
26. Cengiz B., Atabekoglu C., Cetinkaya E., and Cengiz S.D. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas 46 (2003) 301-306
27. Okon M.A., Lee S., Laird S.M., and Li T.C. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy. Hum Reprod 13 (1998) 2261-2265
28. Guha P.K., Villarreal D., Reams G.P., and Freeman R.H. Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 10 (2003) 211-218
29. Hall J.E., Brands M.W., Dixon W.N., and Smith Jr. M.J. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 22 (1993) 292-299
30. Simpson N.K., Johnson C.C., Ogden S.L., Gamito E., Trocky N., McGuire C., et al. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Control Clin Trials 21 (2000) 356S-378S
31. Pinsky P., Miller A., Kramer B.S., Church T., Reding D., Prorok P., et al. Evidence of a health volunteer effect in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Am J Epidemiol 165 (2007) 874-881
32. Lamerato L.E., Marcus P.M., Jacobsen G., and Johnson C.C. Recruitment in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the first phase of recruitment at Henry Ford Health System. Cancer Epidemiol Biomarkers Prev 17 (2008) 827-833